Arsenic triglutathione [As(GS)3] transport by multidrug resistance protein 1 (MRP1/ABCC1) is selectively modified by phosphorylation of Tyr920/Ser921 and Glycosylation of Asn19/Asn23

Molecular Pharmacology

Volumn 90, Issue 2, 2016, Pages 127-139

  Shukalek, Caley B ^a,c   Swanlund, Diane P ^a   Rousseau, Rodney K ^a,d   Weigl, Kevin E ^b   Marensi, Vanessa ^a   Cole, Susan P C ^b   Leslie, Elaine M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC DERIVATIVE; ARSENIC TRIGLUTATHIONE; GLUTATHIONE DERIVATIVE; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; UNCLASSIFIED DRUG; 17-GLUCURONOSYLESTRADIOL; AMINO ACID; ARSENIC; ENZYME INHIBITOR; ESTRADIOL; GLUCURONIC ACID; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; MUTANT PROTEIN; TRYPSIN;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DEGLYCOSYLATION; HEK293 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; KINETIC PARAMETERS; MEMBRANE VESICLE; MOLECULAR WEIGHT; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; TRANSPORT KINETICS; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG EFFECTS; GLYCOSYLATION; KINETICS; METABOLISM; PHOSPHORYLATION; RABBIT; TRANSPORT AT THE CELLULAR LEVEL;

AMINO ACIDS; ANIMALS; ANTIBODIES, MONOCLONAL; ARSENIC; BIOLOGICAL TRANSPORT; ENZYME INHIBITORS; ESTRADIOL; GLUCURONATES; GLYCOSYLATION; HEK293 CELLS; HELA CELLS; HUMANS; KINETICS; METHOTREXATE; MOLECULAR WEIGHT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTANT PROTEINS; PHOSPHORYLATION; RABBITS; TRYPSIN;

EID: 84978634969     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.116.103648     Document Type: Article

References (67)

1. Almquist KC, Loe DW, Hipfner DR, Mackie JE, Cole SP, and Deeley RG (1995) Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drugselected and transfected human tumor cell. Cancer Res 55:102-110.
2. Alp O, Merino EJ, and Caruso JA (2010) Arsenic-induced protein phosphorylation changes in HeLa cells. Anal Bioanal Chem 398:2099-2107.
3. Banerjee M, Carew MW, Roggenbeck BA, Whitlock BD, Naranmandura H, Le XC, and Leslie EM (2014) A novel pathway for arsenic elimination: human multidrug resistance protein 4 (MRP4/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII). Mol Pharmacol 86:168-179.
4. Beauchamp EM, Kosciuczuk EM, Serrano R, Nanavati D, Swindell EP, Viollet B, O'Halloran TV, Altman JK, and Platanias LC (2015) Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on acute myeloid leukemia precursors. Mol Cancer Ther 14:202-212.
5. Beretta GL, Benedetti V, Cossa G, Assaraf YG, Bram E, Gatti L, Corna E, Carenini N, Colangelo D, and Howell SB et al. (2010) Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochem Pharmacol 79:1108-1117.
6. Binyamin L, Assaraf YG, and Reiter Y (2005) Probing ATP-dependent conformational changes in the multidrug resistance protein 1 (MRP1/ABCC1) in live tumor cells with a novel recombinant single-chain Fv antibody targeted to the extracellular N-terminus. Int J Cancer 116:703-709.
7. Blom N, Gammeltoft S, and Brunak S (1999) Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol 294:1351-1362.
8. Büll C, Stoel MA, den Brok MH, and Adema GJ (2014) Sialic acids sweeten a tumor's life. Cancer Res 74:3199-3204.
9. Carew MW and Leslie EM (2010) Selenium-dependent and-independent transport of arsenic by the human multidrug resistance protein 2 (MRP2/ABCC2): implications for the mutual detoxification of arsenic and selenium. Carcinogenesis 31: 1450-1455.
10. Carew MW, Naranmandura H, Shukalek CB, Le XC, and Leslie EM (2011) Monomethylarsenic diglutathione transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Drug Metab Dispos 39:2298-2304.
11. Chen CA and Okayama H (1988) Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques 6:632-638.
12. Cole SP (2014a) Multidrug resistance protein 1 (MRP1, ABCC1), a "multitasking" ATP-binding cassette (ABC) transporter. J Biol Chem 289:30880-30888.
13. Cole SP (2014b) Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future. Annu Rev Pharmacol Toxicol 54:95-117.
14. Cole SP and Deeley RG (2006) Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol Sci 27:438-446.
15. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, and Deeley RG (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902-5910.
16. Deeley RG and Cole SP (2006) Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett 580:1103-1111.
17. Dolniak B, Katsoulidis E, Carayol N, Altman JK, Redig AJ, Tallman MS, Ueda T, Watanabe-Fukunaga R, Fukunaga R, and Platanias LC (2008) Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2. J Biol Chem 283: 12034-12042.
18. Drobná Z, Walton FS, Paul DS, Xing W, Thomas DJ, and Stýblo M (2010) Metabolism of arsenic in human liver: the role of membrane transporters. Arch Toxicol 84:3-16.
19. Ferris SP, Kodali VK, and Kaufman RJ (2014) Glycoprotein folding and qualitycontrol mechanisms in protein-folding diseases. Dis Model Mech 7:331-341.
20. Filippo CA, Ardon O, and Longo N (2011) Glycosylation of the OCTN2 carnitine transporter: study of natural mutations identified in patients with primary carnitine deficiency. Biochim Biophys Acta 1812:312-320.
21. Fujikura Y, Krijt J, and Nećas E (2011) Liver and muscle hemojuvelin are differently glycosylated. BMC Biochem 12:52.
22. Fujimori-Arai Y, Koyama I, Hirano K, and Komoda T (1997) Intestinal alkaline phosphatase isoforms in rabbit tissues differ in glycosylation patterns. Clin Biochem 30:545-551.
23. Galvin JP, Altman JK, Szilard A, Goussetis DJ, Vakana E, Sassano A, and Platanias LC (2013) Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses. Cancer Biol Ther 14:411-416.
24. Gao M, Yamazaki M, Loe DW, Westlake CJ, Grant CE, Cole SP, and Deeley RG (1998) Multidrug resistance protein. Identification of regions required for active transport of leukotriene C4. J Biol Chem 273:10733-10740.
25. Garelick H, Jones H, Dybowska A, and Valsami-Jones E (2008) Arsenic pollution sources. Rev Environ Contam Toxicol 197:17-60.
26. Giafis N, Katsoulidis E, Sassano A, Tallman MS, Higgins LS, Nebreda AR, Davis RJ, and Platanias LC (2006) Role of the p38 mitogen-Activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res 66: 6763-6771.
27. Goussetis DJ and Platanias LC (2010) Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic leukemia. Clin Cancer Res 16: 4311-4312.
28. Hipfner DR, Almquist KC, Leslie EM, Gerlach JH, Grant CE, Deeley RG, and Cole SP (1997) Membrane topology of the multidrug resistance protein (MRP): a study of glycosylation-site mutants reveals an extracytosolic NH2 terminus. J Biol Chem 272:23623-23630.
29. Hipfner DR, Almquist KC, Stride BD, Deeley RG, and Cole SP (1996) Location of a protease-hypersensitive region in the multidrug resistance protein (MRP) by mapping of the epitope of MRP-specific monoclonal antibody QCRL-1. Cancer Res 56:3307-3314.
30. Hipfner DR, Gao M, Scheffer G, Scheper RJ, Deeley RG, and Cole SP (1998) Epitope mapping of monoclonal antibodies specific for the 190-kDa multidrug resistance protein (MRP). Br J Cancer 78:1134-1140.
31. Hipfner DR, Gauldie SD, Deeley RG, and Cole SP (1994) Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res 54:5788-5792.
32. Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, and Skrzypek E (2015) PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res 43:D512-D520.
33. Huyer G, Liu S, Kelly J, Moffat J, Payette P, Kennedy B, Tsaprailis G, Gresser MJ, and Ramachandran C (1997) Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J Biol Chem 272:843-851.
34. International Agency for Research on Cancer (IARC) (2012) A Review of Human Carcinogens: Arsenic, Metals, Fibres and Dusts. World Health Organization IARC, Lyon, France
35. Ito K, Olsen SL, Qiu W, Deeley RG, and Cole SP (2001) Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport. J Biol Chem 276: 15616-15624.
36. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, and Keppler D (1996) Transport of glutathione, glucuronate, and sulfate conjugates by the MRP geneencoded conjugate export pump. Cancer Res 56:988-994.
37. Kala SV, Kala G, Prater CI, Sartorelli AC, and Lieberman MW (2004) Formation and urinary excretion of arsenic triglutathione and methylarsenic diglutathione. Chem Res Toxicol 17:243-249.
38. Kala SV, Neely MW, Kala G, Prater CI, Atwood DW, Rice JS, and Lieberman MW (2000) The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J Biol Chem 275: 33404-33408.
39. Kritharis A, Bradley TP, and Budman DR (2013) The evolving use of arsenic in pharmacotherapy of malignant disease. Ann Hematol 92:719-730.
40. Leslie EM (2012) Arsenic-glutathione conjugate transport by the human multidrug resistance proteins (MRPs/ABCCs). J Inorg Biochem 108:141-149.
41. Leslie EM, Deeley RG, and Cole SP (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204:216-237.
42. Leslie EM, Haimeur A, and Waalkes MP (2004) Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J Biol Chem 279:32700-32708.
43. Loe DW, Almquist KC, Cole SP, and Deeley RG (1996a) ATP-dependent 17 betaestradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J Biol Chem 271:9683-9689.
44. Loe DW, Almquist KC, Deeley RG, and Cole SP (1996b) Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 271:9675-9682.
45. Lozano-Santos C, Amigo-Jiménez I, Nova-Gurumeta S, Pérez-Sanz N, García-Pardo A, and García-Marco JA (2015) Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways. Biochem Biophys Res Commun 461:243-248.
46. Ma L, Krishnamachary N, and Center MS (1995) Phosphorylation of the multidrug resistance associated protein gene encoded protein P190. Biochemistry 34: 3338-3343.
47. Maeno K, Nakajima A, Conseil G, Rothnie A, Deeley RG, and Cole SP (2009) Molecular basis for reduced estrone sulfate transport and altered modulator sensitivity of transmembrane helix (TM) 6 and TM17 mutants of multidrug resistance protein 1 (ABCC1). Drug Metab Dispos 37:1411-1420.
48. Mao Q, Qiu W, Weigl KE, Lander PA, Tabas LB, Shepard RL, Dantzig AH, Deeley RG, and Cole SP (2002) GSH-dependent photolabeling of multidrug resistance protein MRP1 (ABCC1) by [125I]LY475776. Evidence of a major binding site in the COOH-proximal membrane spanning domain. J Biol Chem 277:28690-28699.
49. Mass MJ, Tennant A, Roop BC, Cullen WR, Styblo M, Thomas DJ, and Kligerman AD (2001)Methylated trivalent arsenic species are genotoxic. ChemRes Toxicol 14:355-361.
50. McNeer JL, Goussetis DJ, Sassano A, Dolniak B, Kroczynska B, Glaser H, Altman JK, and Platanias LC (2010) Arsenic trioxide-dependent activation of thousandand-one amino acid kinase 2 and transforming growth factor-beta-Activated kinase 1. Mol Pharmacol 77:828-835.
51. Moremen KW, Tiemeyer M, and Nairn AV (2012) Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol 13:448-462.
52. Mukhopadhyay R, Bhattacharjee H, and Rosen BP (2014) Aquaglyceroporins: generalized metalloid channels. Biochim Biophys Acta 1840:1583-1591.
53. Peng Q, McEuen AR, Benyon RC, and Walls AF (2003) The heterogeneity of mast cell tryptase from human lung and skin. Eur J Biochem 270:270-283.
54. Petrick JS, Ayala-Fierro F, Cullen WR, Carter DE, and Vasken Aposhian H (2000) Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharmacol 163:203-207.
55. Platanias LC (2009) Biological responses to arsenic compounds. J Biol Chem 284: 18583-18587.
56. Ramírez-Solís A, Mukopadhyay R, Rosen BP, and Stemmler TL (2004) Experimental and theoretical characterization of arsenite in water: insights into the coordination environment of As-O. Inorg Chem 43:2954-2959.
57. Reay PF and Asher CJ (1977) Preparation and purification of 74As-labeled arsenate and arsenite for use in biological experiments. Anal Biochem 78: 557-560.
58. Rehman K, Chen Z, Wang WW, Wang YW, Sakamoto A, Zhang YF, Naranmandura H, and Suzuki N (2012) Mechanisms underlying the inhibitory effects of arsenic compounds on protein tyrosine phosphatase (PTP). Toxicol Appl Pharmacol 263: 273-280.
59. Scott H and Panin VM (2014) The role of protein N-glycosylation in neural transmission. Glycobiology 24:407-417.
60. Shukalek CB and Leslie EM (2011) Arsenic triglutathione transport by wild-type, Cys43Ser, and Cys265Ser human multidrug resistance protein 1 (MRP1/ABCC1). Biochem Cell Biol 89:264.
61. Stolarczyk EI, Reiling CJ, Pickin KA, Coppage R, Knecht MR, and Paumi CM (2012) Casein kinase 2a regulates multidrug resistance-Associated protein 1 function via phosphorylation of Thr249. Mol Pharmacol 82:488-499.
62. Stride BD, Grant CE, Loe DW, Hipfner DR, Cole SP, and Deeley RG (1997) Pharmacological characterization of the murine and human orthologs of multidrugresistance protein in transfected human embryonic kidney cells. Mol Pharmacol 52:344-353.
63. Subbarayan PR and Ardalan B (2014) In the war against solid tumors arsenic trioxide needs partners. J Gastrointest Cancer 45:363-371.
64. Verma A, Mohindru M, Deb DK, Sassano A, Kambhampati S, Ravandi F, Minucci S, Kalvakolanu DV, and Platanias LC (2002) Activation of Rac1 and the p38 mitogenactivated protein kinase pathway in response to arsenic trioxide. J Biol Chem 277: 44988-44995.
65. Villa-Bellosta R and Sorribas V (2010) Arsenate transport by sodium/phosphate cotransporter type IIb. Toxicol Appl Pharmacol 247:36-40.
66. Weigl KE (2005) Biochemical Investigations of the Human Multidrug Resistance Protein 1 (MRP1/ABCC1): Analysis of N-Glycosylation and Topology, Queen's University, Kingston.
67. Wen G, Hong M, Calaf GM, Roy D, Partridge MA, Li B, and Hei TK (2010) Phosphoproteomic profiling of arsenite-treated human small airway epithelial cells. Oncol Rep 23:405-412.